Cutia Therapeutics (CUTIA-B) reported that its share capital structure remained unchanged during May 2026. The company’s authorised capital closed the month at 2.50 billion ordinary shares with a par value of USD 0.00002 each, equivalent to total authorised capital of USD 50,000.

The issued share count (excluding treasury shares) stood at 363.37 million, while treasury shares totalled 1.36 million, leaving the overall issued share figure at 364.73 million—identical to the April closing balance. No new shares were issued, and no treasury shares were utilised or cancelled during the period.

Cutia confirmed compliance with the Hong Kong Stock Exchange’s minimum 25 percent public-float requirement as at 31 May 2026.

Equity incentive activity remained dormant. Under the Pre-IPO Share Option Programme, 18.95 million options were outstanding, with no exercises recorded and 18.44 million shares still available for issuance. The Post-IPO Equity Incentive Plan, approved on 30 May 2023, showed no options granted to date but retains capacity for up to 30.40 million shares.

Separately, 16.27 million share awards were outstanding under the Pre-IPO Share Award Programme at the start of May; none vested or were cancelled, leaving 12.41 million shares available for future grants.

Cutia reported no outstanding warrants, convertibles, or other share-linked instruments, and no other movements in issued or treasury shares during the month.

The monthly filing was authorised by Executive Director Zhang Lele and submitted to the Hong Kong Exchanges and Clearing Limited on 4 June 2026.